Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Exploratory Study to Assess the Effect of Treatment With Prolonged-Release Fampridine (BIIB041) 10 mg Twice Daily on Walking Ability and Balance in Subjects With Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Oct 2018
Price :
$35
*
At a glance
- Drugs Fampridine (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms MOBILE
- Sponsors Biogen Idec
- 12 Oct 2018 Results of post hoc integrated efficacy analysis of prolonged-release fampridinevs placebo using MOBILE and ENHANCE data presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- 23 Jun 2015 Patient-reported outcome results presented at the 1st Congress of the European Academy of Neurology.
- 12 Nov 2014 Primary endpoint (Change in subjective impression of well-being measured by Euro Quality of Life-5D (EQ-5D)) has been met according to results presented at the 17th Annual EISPOR.